Medtronic Receives FDA Approval For Its Next Generation Micra Leadless Pacing Systems

Medtronic plc (NYSE: MDT) today announced it has received U.S. Food and Drug Administration (FDA) approval of its Micra ™ AV2 and Micra™ VR2, the next generation of its industry-leading miniaturized, leadless pacemakers. Micra AV2 and Micra VR2, the world's smallest pacemakers, provide longer battery life and easier programming than prior Micra pacemakers, while still delivering the many benefits of leadless paci ng such as reduced complications compared to traditional pacemakers.
Source: News from Angioplasty.Org - Category: Cardiology Source Type: news